Atea’s AT-527 oral antiviral drug candidate reduced viral replication in hospitalized patients with COVID-19
On Jun. 30, 2021, Atea Pharmaceuticals announced positive interim results from the global Phase 2 study evaluating AT-527…
-
-
SIGA supplied TPOXX (Tecovirimat) as compassionate treatment for Mpox case in the Central African Republic
On Jul. 29, 2021, SIGA Technologies announced that it had entered into a collaboration with Oxford University in…
-
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | FDA | Genomics | Life Science History | Medicine | NIH | Therapeutics | U.S. Congress | Vaccine
COVID-19 PPE distribution
The COVID-19 PPE Distribution cartoon illustrates the confusion and complexity of distributing Personal Protective Equipment (PPE) to defend…
-
Oxford researchers identified levels of antibody protection required to prevent symptomatic COVID-19
On Jun. 25, 2021, researchers from the University of Oxford released their findings about the so-called ”correlates of…
-
Roche’s Actemra/RoActemra received FDA EUA for treatment of COVID-19 in hospitalised adults and children
On Jun. 25, 2021, Roche announced that the Food and Drug Administration (FDA) had issued an Emergency Use…
-
Disease | FDA | Neurology | Therapeutics
Eisai and Biogen announced FDA granted Breakthrough Therapy Designation for Lecanemab for treatment of Alzheimer’s disease
On Jun. 23, 2021, Biogen and Eisai announced that the U.S. Food and Drug Administration (FDA) had granted…
-
NIH study suggested COVID-19 prevalence far exceeded early pandemic cases
On Jun. 22, 2021, National Institutes of Health researchers reported that the prevalence of COVID-19 in the U.S….
-
Construction of the Biologics Manufacturing Centre in Montreal completed
On Jun. 22, 2021, the National Research Council of Canada (NRC) announced it had completed construction of the…
-
Gilead’s Veklury (Remdesivir) associated with reduction in mortality rate in hospitalized patients with COVID-19
On Jun. 21, 2021, Gilead Sciences announced positive data from three retrospective studies of the real-world treatment of…
-
Newly licensed U.S. manufacturing facility increased availability of Fluzone high-dose quadrivalent (influenza vaccine)
On Jun. 17, 2021, the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research granted…
-
RECOVERY trial found Regeneron’s monoclonal antibody combination reduced deaths for hospitalised COVID-19 patients
On Jun. 16, 2021, the University of Oxford announced the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial demonstrated…
-
Biotechnology | COVID-19 | Disease | Therapeutics | Vaccine
REGEN-COV phase 3 RECOVERY trial met primary outcome, improving survival in Hospitalized COVID-19 patients
On Jun. 16, 2021, Moderna announced that the U.S. government had purchased an additional 200 million doses of…
-
Cocrystal’s COVID-19 antiviral CDI-45205 shown to be active against SARS-CoV-2 and prominent SARS-CoV-2 variants
On Jun. 14, 2021, Cocrystal Pharma announced that its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active…
-
University of British Columbia researchers received the New Frontiers in Research Fund 2020 Exploration award
On Jun. 14, 2021, University of British Columbia researchers Dr. Jayachandran Kizhakkedathu, Dr. Caigan Du and Dr. Christopher…
-
Merck announced supply agreement with U.S. Government for molnupiravir, an Investigational oral antiviral treatment of COVID-19
On Jun. 9, 2021, Merck announced it had entered into a procurement agreement with the United States government…
-
Vertex announces FDA approval for TRIKAFTA in children with Cystic Fibrosis ages 6 through 11 with certain mutations
On Jun. 9, 2021, Vertex Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approved expanded use of…
-
Twist Bioscience began shipping of synthetic RNA controls for Kappa (B.1.617.1) SARS-CoV-2 variants
On Jun. 8, 2021, Twist Bioscience announced that it has started shipping its synthetic RNA reference controls for…
-
Senolytics reduced COVID-19 symptoms in preclinical studies
On Jun. 8, 2021, Mayo Clinic researchers and colleagues at the University of Minnesota showed that COVID-19 exacerbates…
-
MediciNova initiated sheep study under BARDA to develop MN-166 (ibudilast) as countermeasure against chlorine
On Jun. 7, 2021, MediciNova announced it had initiated a sheep study to investigate MN-166 (ibudilast) in an…
-
Biotechnology | Disease | FDA | Neurology | Therapeutics
FDA granted accelerated approval for ADUHELM as the first and only Alzheimer’s disease treatment
On Jun. 7, 2021, Biogen and Eisai announced that the U.S. Food and Drug Administration (FDA) had granted…
-
FDA approved new rug treatment for chronic weight management, first since 2014
On Jun. 4, 2021, the U.S. Food and Drug Administration (FDA) announced it had approved Novo Nordisk’s Wegovy…
-
FDA authorized lower 1,200 mg intravenous and subcutaneous dose of REGEN-COV antibody cocktail to treat COVID-19 patients
On Jun. 4, 2021, Regeneron announced the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization…
-
Resverlogix and EVERSANA announced partnership to support commercialization of Apabetalone for COVID-19 in U.S. and Canada
On Jun. 3, 2021, Resverlogix announced a partnership to support planned commercialization of apabetalone in the United States…
-
NIH researchers identified potential new antiviral drug for COVID-19
On Jun. 3, 2021, the National Institutes of Health (NIH) announced that the experimental drug TEMPOL may be…
-
Innovation Pharma completed enrollment in phase 2 clinical trial for COVID-19
On Jun. 3, 2021, Innovation Pharma announced that it had achieved full patient enrollment in its randomized, double-blind,…
-
Relief Therapeutics reported that NRx Pharma, had submitted an application for EUA for Aviptadil to the U.S. FDA
On Jun. 2, 2021, NRx Pharmaceuticals announced it had filed an application with U.S. Food and Drug Administration…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Non-Profit Research | Therapeutics | Vaccine | WHO
WHO $50 billion health, trade and finance roadmap to end the pandemic and secure a global recovery
On Jun. 1, 2021, the heads of the world’s predominant global financing, health and trade agencies united to…
-
CytoDyn received first order from Chiral Pharma for use of Leronlimab for COVID-19 patients in the Philippines
On Jun. 1, 2021, CytoDyn announced that Chiral Pharma in the Philippines placed its first purchase order for…
-
HHS launched first venture capital partnership to develop transformative technologies to combat future pandemics
On Jun. 1, 2021, the U.S. Department of Health and Human Services (HHS) unveiled a new type of…
-
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics
FDA approved LUMAKRAS for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
On May 28, 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved LUMAKRAS (sotorasib)…
